Updates in Retinal Disease Care: Keeping an Eye on Emerging Anti-VEGF Therapies & Improved Outcomes

The prevalence of retinal diseases such as age-related macular degeneration and diabetic macular edema is projected to rise dramatically in the coming decades with an aging population and the increasing prevalence of diabetes. The availability of anti-vascular endothelial growth factor (VEGF) therapies has significantly improved outcomes for patients with retinal disease for over a decade. However, the need for frequent intravitreal injections required to obtain the best possible patient outcomes with anti-VEGF therapies has added to the patient burden associated with retinal disease management. This also led many clinicians and patients to opt for as-needed dosing intervals guided by optical coherence tomography results, which may be more expedient for patients but has also been associated with worsening of retinal disease and vision loss. Thus, an unmet need persists for more efficacious therapies with increased duration of response to minimize the number of injections required for the many patients with retinal disease. There are newly available therapeutic options, such as the port delivery system with ranibizumab and the dual anti-VEGF, anti-Ang-2 binding faricimab; along with several emerging, novel therapies including sustained-release anti-VEGF formulations, combination anti-VEGFs, and gene therapy.

Share

Program Content

Activities

  • Updates in Retinal Disease Care
    Updates in Retinal Disease Care: Keeping an Eye on Emerging Anti-VEGF Therapies & Improved Outcomes
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2022

    Expires: December 20, 2023

Faculty

cover img faculity

Nancy Holekamp, MD

Professor of Clinical Ophthalmology and Visual Sciences
Washington University School of Medicine
St Louis, MO
Director of Retina Services
Pepose Vision Institute
Chesterfield, MO

cover img faculity

Carl Regillo, MD

Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, PA

Provided by

ProCE Banner
ProCE Banner

Jointly provided by the Potomac Center for Medical Education and Rockpointe.

Supporters

Supported by an educational grant from Genentech, a member of the Roche Group.

Genentech, a member of the Roche Group